Author
Sigurður Yngvi Kristinsson, MD, PhD (University of Iceland— Reykjavík, Iceland) Dr. Kristinsson is the principal investigator of the iStopMM (Iceland Screens, Treats, or Prevents Multiple Myeloma) Project. He is a Professor of Hematology at the University of Iceland in…
Author
Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCOInternational Myeloma Foundation Medical AdvisorTGen, City of Hope Cancer Center—Phoenix, AZ, USADr. Mikhael is a Professor in the Applied Cancer Research and Drug Discovery Division at the Translational…
Videos
The Phase 3 MajesTEC-3 trial, the first randomized study of bispecific antibody therapy in multiple myeloma, evaluated teclistamab plus daratumumab (Tec-Dara) versus standard-of-care triplet regimens (daratumumab with pomalidomide-dexamethasone or bortezomib-dexamethasone) in 587 patients with…
Videos
The inMMyCAR Phase 1 study evaluated KLN-1010, a groundbreaking in vivo gene therapy that creates anti-BCMA CAR-T cells directly inside the patient's body for treating relapsed and refractory multiple myeloma, eliminating the need for cell collection (apheresis), custom manufacturing, or…
Videos
Top 10 Multiple Myeloma Breakthroughs from ASH 2025What the Latest CAR T-cell and Bispecific Antibody Research Means for Patients and FamiliesEvery year, the American Society of Hematology (ASH) annual meeting brings together thousands of researchers, physicians, and patient advocates from around…
Videos
DOWNLOAD SLIDES Key Highlights from ASH 2025 – Myeloma Updates Event OverviewASH (American Society of Hematology) hosted its largest annual meeting with…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the January 2026 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
On Tuesday, January 6, Johnson & Johnson announced via …
Videos
The multi-center study analyzed 761 relapsed multiple myeloma patients receiving standard-of-care ciltacabtagene autoleucel (cilta-cel) across 15 U.S. centers from May 2022 to December 2024 to identify modifiable risk factors for Parkinsonism and non-relapse mortality. Non-response to bridging…
News Article
2025 IMF Nurse Leadership Board Annual MeetingBy Diane Moran, IMF Interim Chief Executive Officer, Senior Vice President, Strategic PlanningScope / MethodologyThis article summarizes key discussions, initiatives, and outcomes from the 2025 IMF Nurse Leadership Board (NLB) Annual…
Videos
Myeloma in a Minute or Less: How to Manage Pain with Multiple Myeloma Pain is an unfortunate reality for many people living with multiple myeloma, but it can be managed. In this Myeloma in a Minute or Less video, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the December 2025 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
Page
The CRAB CriteriaThe IMF International Myeloma Working Group (IMWG), the research arm of the IMF, is one of the most prestigious organizations for myeloma experts. IMWG members conduct collaborative basic, clinical, and translational research to improve outcomes for patients while providing…
News Article
On Monday, December 15, Johnson & Johnson announced via press release that the U.S. Food and Drug Administration…
News Article
December 9, 2025—According to a press release from Johnson & Johnson, there is "new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as early…
Videos
What Myeloma Patients and Care Partners Need to Know from ASH 2025 | Facebook Live ReplayThe International Myeloma Foundation (IMF) went live from the American Society of Hematology (ASH) Annual Meeting in Orlando to help patients and care partners make sense of the latest research in multiple…
News Article
Poster Abstracts 4570, 4578, and 6347 to be presented on December 7–8 at the 67th ASH Annual Meeting and Exposition in Orlando, FL. STUDIO CITY, CA, Dec. 7, 2025 — The International Myeloma Foundation (IMF) is proud to announce that Abena Prempeh (…
News Article
2025 IMF Brian D. Novis Research GrantsBy Lisa Paik, IMF Executive Vice President, Research & OperationsScope / MethodologyThis article provides an overview of the 2025 Brian D. Novis Research Grants awarded by the International Myeloma Foundation (IMF). Content was developed…
Page
Myeloma in a Minute or Less: Fast, Expert Answers for Multiple MyelomaMyeloma in a Minute or Less is a fast, focused video series from the International Myeloma Foundation that delivers bite-sized, expert insights on multiple myeloma—all in under 60 seconds.Hosted by Dr. Joseph Mikhael, IMF Chief…
Page
#AskTheIMF: Your Trusted Source for Multiple Myeloma Questions & Expert AnswersLiving with multiple myeloma often comes with more questions than answers. That is why #AskTheIMF exists.Hosted by the International Myeloma Foundation, this trusted Q&A video series connects patients, care…
Videos
Can Multiple Myeloma Ever Be Prevented or Even Cured Before It Becomes Active? | An Interview with Dr. Shaji KumarIn this in-depth interview, Dr. Shaji Kumar, hematologist at Mayo Clinic and member of the IMF's Scientific Advisory Board and International Myeloma Working Group (IMWG), explains what…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the November 2025 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
IMF Person
Heather Cooper Ortner brings deep institutional knowledge and executive leadership to her role as President & CEO of the International Myeloma Foundation. With longstanding ties to the IMF—including seven years with the organization and prior service as Executive Vice President of Development—…
News Article
35 Years of Defying Boundaries and Redefining PossibilitiesWhen the International Myeloma Foundation (IMF) was founded in 1990, it was the first organization focused specifically on multiple myeloma, and it remains the largest and only global organization in the field. What made the IMF…
Videos
Will Myeloma Ever Be Curable? Answering Real Multiple Myeloma Patient QuestionsIn this IMF Q&A, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, tackles some of the most asked, and most emotional, questions from myeloma patients and care partners. From…
Videos
A Rigorous Journey to End Myeloma In 2024, a team of 15 determined individuals—multiple myeloma survivors, care partners, and world-renowned physicians—embarks on the Iceland Cycling Expedition (ICE). Their mission: to cycle through Iceland's rugged landscape to raise critical funds for…
Videos
DOWNLOAD SLIDES
News Article
2025 Blood Cancer Awareness Month‘Do You #kNOwMyeloma?’ reaches more than 25 million in 62 countries!By Peter Anton, IMF Vice President, MarketingFor the 2025 Blood Cancer Awareness Month (BCAM), the International Myeloma Foundation (IMF) revived its highly successful #…
Videos
Your Myeloma Questions Answered: PET Scans, Side Effects, and New Treatment OptionsIn this Q&A, Dr. Joseph Mikhael, Chief Medical Officer of the International Myeloma Foundation, answers real questions submitted by patients and care partners from our social media comments section. From PET…
News Article
November 6, 2025—According to this press release, "the Food and Drug Administration approved…
Videos
25 Years With Multiple Myeloma: Michael & Robin Tuohy’s Journey of Hope and ResilienceFor More Than 25 Years, Michael and Robin Tuohy Have Faced Multiple Myeloma Together—Patient and Care Partner, Husband and Wife, Advocates and Leaders Within the International Myeloma Foundation (IMF)…
Videos
High-Risk Smoldering Myeloma & New Frontline Treatments: What Patients Need to Know | IMS Part 2 of 2In this video, IMF Chief Medical Officer Dr. Joseph Mikhael breaks down the most important research updates from the International Myeloma Society (IMS) annual meeting with a focus on what these…
Page
2025 Global Myeloma Action Network (GMAN) Summit Report The Global Myeloma Action Network (GMAN) Summit A summary report from the 2025 GMAN Annual Meeting, which took place in person from June 6-8, 2025, in Milan, Italy. The Global Myeloma Action Network® (GMAN…
Page
International Myeloma Working Group Summit The 2025 IMWG annual meeting took place in-person from June 9-11, 2025, in Milan, Italy.Emerging from the IMF Scientific Advisory Board (est. 1995), the International Myeloma Working Group’s (IMWG) mission is to identify and implement the most…
Audio
Dr. Joseph Mikhael, Chief Medical Officer, talks about the IMF’s ongoing efforts and future goals in the fight against myeloma. He heads the IMF’s M-Power Project, which aims to improve care for African Americans—who are diagnosed with myeloma at twice the rate of white individuals…
News Article
On Thursday, October 23, 2025, the U.S. Food and Drug Administration (FDA) announced its approval of…
Page
One of the ways the IMF's Global Myeloma Action Network® (GMAN®) accomplishes its mission is by awarding Susie Novis Durie (SND) Educational Grants to patient advocacy organizations to elevate their work. Here are the 2025 SND Grant Recipients:Armenia: Armenian Hematology Association“Myeloma…
Videos
IMS Highlights: Frontline Wins, High-Risk Insights, and What’s Next in Myeloma | Part 1 of 2Dr. Joseph Mikhael (IMF Chief Medical Officer) breaks down the biggest takeaways from the International Myeloma Society meeting. He discusses what matters now for patients and care partners. In this…
News Article
At the end of every month, the International Myeloma Foundation Newsroom will feature a wrap-up of some of the most fascinating studies about multiple myeloma from medical journals. Here is the October 2025 edition.The IMF team of medical editors has provided overviews of key studies. Yet, we…
News Article
According to Johnson & Johnson, results of the Phase 3 MajesTEC-3 study reveal TECVAYLI® plus DARZALEX FASPRO® combination significantly improves PFS and overall survival.
On Thursday, October 16, Johnson & Johnson announced “positive topline results from the…
News Article
Dr. James Chim to Receive Asian Myeloma Network Distinguished Service Award at the 9th AMN Summit in Nagoya
International Myeloma Foundation (IMF) to hold AMN Awards Ceremony at the 9th AMN Summit in Nagoya, Japan on Saturday, October 18.
NAGOYA, JAPAN, October 16, 2025…
Videos
This educational webinar from the International Myeloma Foundation featured Dr. Beth Faiman (Cleveland Clinic) and Dr. Zainab Shahid (Memorial Sloan Kettering) discussing infection risks in multiple myeloma patients and prevention strategies. The presentation covered why myeloma patients face…
Videos
Multiple Myeloma: Love, Advocacy, and 10 Years of Hope
When Terrence Green was hospitalized for weeks with no improvement, doctors discovered he had multiple myeloma. His wife, Toni, became his strongest advocate, asking questions, keeping records, and standing beside him through every step.…
News Article
The Global Myeloma Community Mourns the Passing of IMF Co-Founder Dr. Brian G.M. Durie
LOS ANGELES, October 14, 2025 — It is with great sadness that the International Myeloma Foundation (IMF) shares the news of the death of Dr. Brian G.M. Durie, co-founder of the…
Page
Dr. Durie was a visionary in the field of myeloma, a type of blood cancer that affects plasma cells. His 1975 pioneering work, the Durie-Salmon Staging System, shed light on the myeloma tumor burden and how it impacts other cellular functions. A prolific researcher, Dr. Durie authored over 700…
Videos
How a Clinical Trial Changed Joan's Life
How Joan Turned a Myeloma Diagnosis Into Hope Through a Clinical Trial
Joan shares her inspiring journey with multiple myeloma, from her initial diagnosis with monoclonal gammopathy of undetermined significance (MGUS) to joining a clinical trial that…